AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases)
Form 10-Q / 10-K Contingencies Note
Latest, FY2025
75
Period ended Dec 31, 2025
Change on a year earlier
0.0%
75 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 75 | 0.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 75 | – | Form 10-K (filed 2025-02-14) ↗ |
Breakdown
What makes up pending legal claims — biocell textured breast implant alcl state lawsuits (cases)
Cite this data
StockData. (2026). AbbVie Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases), annual FY2024–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit_biocell_state
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.